Michelle Gilson
Stock Analyst at Morgan Stanley
(1.15)
# 3,403
Out of 4,829 analysts
31
Total ratings
32.14%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $5.30 | +277.36% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $72.14 | -58.41% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $3.73 | +355.76% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $154.43 | +26.92% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $21.54 | +108.91% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $9.66 | +686.75% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $61.37 | +48.28% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $5.30
Upside: +277.36%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $72.14
Upside: -58.41%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $3.73
Upside: +355.76%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $154.43
Upside: +26.92%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $21.54
Upside: +108.91%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $9.66
Upside: +686.75%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $61.37
Upside: +48.28%